Agreed and if the company had been committing fraud against their investors do you think the FDA would lift the hold... Seems like management would lose all credibility in the eyes of the FDA.
Shorts like to move to this argument instead of looking at outcome based upon trial enrollment.
Any failure of endpoints in addition to having to report these failures to the FDA, the company would have to advise investors of under sec regulations.
Ah, another investor who can't wrap their head around the fact that a futility rec does not mean failure.
(It just means it's likely to fail if allowed to proceed)